Land: Malta
Sprache: Englisch
Quelle: Medicines Authority
CAPECITABINE
Fresenius Kabi Oncology PLC Lion Court, Farnham Road, Bordon, Hampshire, GU35 0NF, United Kingdom
L01BC06
CAPECITABINE 500 mg
FILM-COATED TABLET
CAPECITABINE 500 mg
POM
ANTINEOPLASTIC AGENTS
Withdrawn
2013-04-08
Page 1 of 8 PACKAGE LEAFLET: INFORMATION FOR THE USER CAPECITABINE FRESENIUS KABI 150 MG FILM-COATED TABLETS CAPECITABINE FRESENIUS KABI 500 MG FILM-COATED TABLETS capecitabine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. IN THIS LEAFLET: 1. What Capecitabine is and what it is used for 2. What you need to know before you take Capecitabine 3. How to take Capecitabine 4. Possible side effects 5. How to store Capecitabine 6. Contents of the pack and other information 1. WHAT CAPECITABINE IS AND WHAT IT IS USED FOR Capecitabine belongs to the group of medicines called "cytostatic medicine", which stop the growth of cancer cells. Capecitabine Fresenius Kabi film-coated tablets contains 150 mg or 500 mg capecitabine, which itself is not a cytostaticmedicine. Only after being absorbed by the body is it changed into an active anti-cancer agent (more in tumour tissue than in normal tissue). Capecitabine is used in the treatment of colon, rectal, gastric, or breast cancers. Furthermore, capecitabine is used to prevent new occurrence of colon cancer after complete removal of the tumour by surgery. Capecitabine may be used either alone or in combination with other agents. 2. WHAT YOU NEED TO KNOW BEFORE Lesen Sie das vollständige Dokument
Page 1 of 24 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Capecitabine 500 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 500 mg capecitabine. Excipient (s) with known effect: 41 mg lactose monohydrate (500 mg tablet). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Pink coloured, capsule shaped, biconvex, film coated tablets, debossed with “500”on one side and plain on other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Capecitabine is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer (see section 5.1). Capecitabine is indicated for the treatment of metastatic colorectal cancer (see section 5.1). Capecitabine is indicated for first-line treatment of advanced gastric cancer in combination with a platinum- based regimen (see section 5.1). Capecitabine in combination with docetaxel (see section 5.1) is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Capecitabine should only be prescribed by a qualified physician experienced in the utilisation of anti- neoplasticmedicinal products. Careful monitoring during the first cycle of treatment is recommended for all patients. Lesen Sie das vollständige Dokument